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Abstract
Purpose: To evaluate the in vitro inactivation of severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) with hydrogen peroxide (H2 O2 ) and povidone-iodine
(PVP-I) oral antiseptic rinses at clinically recommended concentrations and contact
times.
Materials and Methods: SARS-CoV-2, USA-WA1/2020 strain virus stock was prepared prior to testing by growing in Vero 76 cells. The culture media for prepared
virus stock was minimum essential medium (MEM) with 2% fetal bovine serum
(FBS) and 50 µg/mL gentamicin. Test compounds consisting of PVP-I oral rinse
solutions and H2 O2 aqueous solutions were mixed directly with the virus solution
so that the final concentration was 50% of the test compound and 50% of the virus
solution. Thus PVP-I was tested at concentrations of 0.5%, 1.25%, and 1.5%, and
H2 O2 was tested at 3% and 1.5% concentrations to represent clinically recommended
concentrations. Ethanol and water were evaluated in parallel as standard positive
and negative controls. All samples were tested at contact periods of 15 seconds and
30 seconds. Surviving virus from each sample was then quantified by standard endpoint dilution assay and the log reduction value of each compound compared to the
negative control was calculated.
Results: After the 15-second and 30-second contact times, PVP-I oral antiseptic
rinse at all 3 concentrations of 0.5%, 1.25%, and 1.5% completely inactivated SARSCoV-2. The H2 O2 solutions at concentrations of 1.5% and 3.0% showed minimal
viricidal activity after 15 seconds and 30 seconds of contact time.
Conclusions: SARS-CoV-2 virus was completely inactivated by PVP-I oral antiseptic rinse in vitro, at the lowest concentration of 0.5 % and at the lowest contact time
of 15 seconds. Hydrogen peroxide at the recommended oral rinse concentrations of
1.5% and 3.0% was minimally effective as a viricidal agent after contact times as
long as 30 seconds. Therefore, preprocedural rinsing with diluted PVP-I in the range
of 0.5% to 1.5% may be preferred over hydrogen peroxide during the COVID-19
pandemic.

The coronavirus disease 2019 (COVID-19) pandemic caused
by the severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) has resulted in exceptional challenges to
infection control procedures in the dental office.1,2 Human
modes of transmission of SARS-CoV-2 from infected individuals can occur by simple procedures such as breathing,
talking, coughing or sneezing.2,3 It has been accepted that

the oral cavity including oropharynx, and the nasopharynx
have the highest viral loads.2-4 Adding to the risk is the
nature of dental care, which involves close physical contact
of dental professionals with patients, and constant exposure
to saliva which is known to have a high load of oral microbes
including virus.2-4 Therefore, any dental procedure, especially
prosthodontic procedures, which can aerosolize contaminated
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saliva (using handpieces, air-water syringes, and ultrasonic
instrumentation), has the potential to significantly increase
airborne transmission of the virus.5-7 All of this places dental
professionals at a significantly higher risk for infection, and be
a source for further transmission of infection. This behooves
dental professionals to consider additional and augmented
protocols for infection control in the dental office.6,7
The nasal and oral cavities are considered a major portal of
entry for SARS-CoV-2, and are directly associated with the
evolutionary process of COVID-19. They are involved in inhalation of virus containing droplet particles and aerosols in the
ambient regions, as well as in expectorations of virus containing droplets.8,9 Therefore, a significant amount of attention has
been paid during the COVID-19 pandemic towards enhancing
personal protection equipment (PPE) for dental professionals.9
Some examples include higher particulate filtration masks (N95), respirators and face shields.9-11 Additional equipment such
as routine use of high efficiency particulate air (HEPA) filters
and improved designs for high volume evacuator (HEV) have
also been advocated.10,11
An additional component of protection that has recently begun to receive increased attention is the use of preprocedural oral rinses.2,3,7,12 Due to the knowledge that the oropharyngeal region is a major site of viral replication during the
early asymptomatic stages of COVID-19, it has been suggested that oral antiseptic rinses that target the lipid envelope
of SARS- CoV-2, has the potential to reduce viral load in the
oropharynx.12 There is increasing recognition that oral antiseptic rinses with significant viricidal activity may have a role
as potential therapeutic agents to inactivate infective particles
generated in the oropharyngeal region.7,12,13 Recent articles
have discussed the importance of preprocedural oral antiseptic
rinses for use on patients as well as dental and medical professionals, in order to reduce the risk of transmission associated
with viral shedding from asymptomatic individuals.6,7,14
A variety of oral antiseptic rinses have been suggested
in recent literature for preprocedural use to reduce viral
transmission.12 Oral rinses ranging from chlorhexidine gluconate, ethanol, essential oils, povidone-iodine (PVP-I), hydrogen peroxide (H2 O2 ) chlorinated water, hypertonic saline,
bioflavonoids, cyclodextrins, cetylpyridinium chloride have
been recommended.10-12 Presently, there are no clinical studies reported on any oral antiseptic rinses specifically against
SARS-CoV-2. A recent in vitro study of PVP-I oral rinses has
demonstrated complete inactivation of SARS-CoV-2 at concentrations between 0.5% and 1.5% and contact times as little as 15 seconds.7 Though PVP-I solutions at concentrations
below 2.5% have been demonstrated to be safe for routine,
repeated use in the oral cavity, they are not recommended
for patients with active thyroid disease, pregnancy, anaphylactic allergy, and in patients undergoing radioactive iodine
therapy.15-17
Therefore, it would be helpful to study alternatives to PVP-I
to mitigate these contraindications to allow a broader population to seek the benefits of preprocedural oral rinsing. Hydrogen peroxide oral rinse is a popular rinse anecdotally used
by dentists due to its long history of use in teeth whitening
procedures.18,19 It has also been recommended by the American Dental Association (ADA) as a preprocedural rinse op2
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tion during the COVID-19 pandemic.10 Some of the advantages of H2 O2 include easy accessibility, low cost, and longtrack record in dentistry.18,19 However its disadvantages include its potential for toxicity under routine use by dental
professionals,18 gastric and colon disturbances,20 inactivation
in the mouth due to host catalase activity in the saliva,21 and
absence of any clinical or in vitro evidence for viricidal activity against SARS-CoV-2.12
The purpose of this study was to compare in vitro inactivation of SARS CoV-2 with hydrogen peroxide (H2 O2 )
and povidone-iodine (PVP-I) oral antiseptic rinses at clinically recommended concentrations and clinically convenient
timescales. The null hypotheses were that there would be no
difference between viricidal activity of H2 O2 and PVP-I and
that there would be no difference in viricidal activity at varied
concentrations and contact times for both types of oral rinses.

Materials and methods
All laboratory procedures with SARS-CoV-2 was conducted
in biosafety level 3 (BSL-3) laboratories at The Institute for
Antiviral Research at Utah State University at Logan, Utah,
following established standard operating procedures approved
by the Utah State University Biohazards Committee. Hydrogen peroxide 6% (w/w) and 3% (w/w) oral rinse solutions
were prepared from dilution of purified United States Pharmacopeia (USP) grade hydrogen peroxide 30% aqueous solutions
(Sigma-Aldrich; St. Louis, MO) with sterile deionized water.
Povidone-iodine (PVP-I) oral rinse antiseptic solutions (Veloce
BioPharma; Fort Lauderdale, FL) at concentrations of 3.0%,
2.5%, and 1.0% were prepared as well. SARS-CoV-2, USAWA1/2020 strain, virus stock was prepared prior to testing by
growing in Vero 76 cells. Culture media for the prepared stock
(test media) was minimum essential medium (MEM) with 2%
fetal bovine serum (FBS) and 50 µg/mL gentamicin.
The 5 test compounds were then incubated in a 1:1 ratio with
the virus solution so that the final concentration of each individual test compound was 50% of the starting concentration.
The test solutions were chosen to represent the recommended
PVP-I and peroxide rinse concentrations after 1:1 dilution with
virus stock solution, in order to evaluate the clinically significant concentrations. A single concentration of each sample was
tested in triplicate. Test media without any virus was added to
2 tubes of the compounds to serve as toxicity and neutralization controls. Ethanol (70%) was tested in parallel as a positive
control and water only, as a negative control. Incubation times
of 15 seconds and 30 seconds were chosen to represent reasonable and conveniently achievable rinse and gargle times for
both patients and providers in clinical settings. The test solutions and virus were incubated at room temperature (22 ± 2°C)
for 15 seconds and for 30 seconds per standard testing protocols. The solutions were then neutralized by a 1/10 dilution in
MEM with 2% FBS, 50 µg/mL gentamicin.
The surviving virus from each sample was quantified by standard end-point dilution assay. Briefly, the neutralized samples
were pooled and serially diluted using eight log dilutions in
test medium. Then 100 µL of each dilution was plated into
quadruplicate wells of 96-well plates containing 80% to 90%
confluent Vero 76 cells. The toxicity controls were added to
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Table 1 Viricidal efficacy of test compounds against SARS-CoV-2 after a 15-second incubation with virus at 22 ± 2°C

Test product
PVP-I 1.0% Oral Rinse
PVP-I 2.5% Oral Rinse
PVP-I 3.0% Oral rinse
H2 O2 3.0%
H2 O2 6.0%
Ethanol Control
Virus Control
a
b

Percent
concentration of
PVP-I as tested

Percent
concentration of
H2 O2 as tested

Incubation time
(in seconds)

Virus titer

LRV

0.5
1.25
1.5
0
0
N/A
N/A

0
0
0
1.5
3.0
N/A
N/A

15
15
15
15
15
15
15

<0.67
<0.67
<0.67
≤3.67
≤4.0
<0.67
5.0

>4.33
>4.33
>4.33
1.33
1.00
>4.33
N/A

a

b

Log10 CCID50 of virus per 0.1 mL. The assay lower limit of detection is 0.67 Log10 CCID50/0.1 mL.
LRV (log reduction value) is the reduction of virus compared to the virus control.

Table 2 Viricidal efficacy of test compounds against SARS-CoV-2 after a 30-second incubation with virus at 22°C to 2°C

Test product
PVP-I 1.0% Oral Rinse
PVP-I 2.5% Oral Rinse
PVP-I 3.0% Oral rinse
H2 O2 3.0%
H2 O2 6.0%
Ethanol Control
Virus Control
a
b

Percent
concentration of
PVP-I as tested

Percent
concentration of
H2 O2 as tested

Incubation
time (in
seconds)

Virus titer

LRV

0.5
1.25
1.5
0
0
N/A
N/A

0
0
0
1.5
3.0
N/A
N/A

30
30
30
30
30
30
30

<0.67
<0.67
<0.67
≤3.33
≤2.5
<0.67
4.3

>3.63
>3.63
>3.63
1.0
1.8
>3.63
N/A

a

b

Log10 CCID50 of virus per 0.1 mL. The assay lower limit of detection is 0.67 Log10 CCID50/0.1 mL.
LRV (log reduction value) is the reduction of virus compared to the virus control.

an additional 4 wells of Vero 76 cells and 2 of those wells at
each dilution were infected with virus to serve as neutralization controls, ensuring that residual sample in the titer assay
plate did not inhibit growth and detection of surviving virus.
Plates were incubated at 37 ± 2°C with 5% CO2 for 5 days.
Each well was then scored for presence or absence of infectious virus by examining for any cytopathic effect (CPE) in
the wells. Briefly, after incubation in wells of known dilution
containing susceptible cells, if any active virus was present at
the start of the incubation, the virus grew resulting in a CPE
in the wells where it was plated. Using the CPE count and the
dilution of that well, the concentration that allowed the virus
to grow in the cells and cause the CPE, were used for calculation. The titers were then measured using a standard endpoint
dilution 50% cell culture infectious dose (CCID50) assay calculated using the Reed-Muench equation.22 Subsequently, the
log reduction value (LRV) of each compound compared to the
negative (water) control was calculated.

Results
The virus titers and log reduction value of SARS-CoV-2 when
incubated with a single concentration of the test compounds
for 15 seconds are shown in Table 1. After the 15-second contact period, all 3 of the PVP-I tested solutions were effective at reducing >4.33 log10 CCID50 infectious virus from

5.0 log10 CCID50/0.1 mL to <0.67 log10 CCID50/0.1 mL.
The H2 O2 solutions at the clinically recommended and commercially available concentrations of 3.0% and 1.5% had minimal viricidal activity after 15 seconds. Table 2 shows the virus
titers and LRV of SARS-CoV-2 when the virus was incubated
for 30 seconds with each of the 5 test compounds at 50/50 ratio. For the 30-second second contact time, the compounds had
nearly the same effect as the 15 second contact time, with PVPI showing more effective viricidal activity than H2 O2. Both the
positive control (ethanol) and neutralization controls (water)
performed as anticipated.

Discussion
The purpose of this study was to compare in vitro inactivation of SARS CoV-2 with hydrogen peroxide (H2 O2 ) and
povidone-iodine (PVP-I) oral antiseptic rinses at different
clinically recommended concentrations and contact times of
15 seconds and 30 seconds. The first null hypothesis related
to the comparison of the 2 tested oral rinses was rejected and
the second null hypothesis related to contact times for PVP-I
was not rejected. The findings from this study confirm the results of a recent study by Bidra et al7 which also showed that
PVP-I oral rinses completely inactivated SARS CoV-2 with
a concentration as low as 0.5% and contact time as low as
15 seconds.
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The Centers for Disease Control and Prevention (CDC) has
suggested chlorhexidine gluconate, essential oils, PVP-I or
cetylpyridinium chloride as options for preprocedural rinsing
before dental procedures.11 The American Dental Association
(ADA) interim guidelines has suggested only 1.5% H2 O2 or
0.2% PVP-I as options for preprocedural oral rinsing.10 Findings from this study showed that H2 O2 had weak viricidal
activity and the log reduction value for low-concentrations
of PVP-I were three times higher than H2 O2 at the tested
concentrations and contact times. It is possible that commercially available H2 O2 oral rinses may have additional ingredients incorporated to improve the viricidal activity and that the
viricidal activity may be better or worse at increased contact
times. However, the 15- and 30-second contact times were chosen to represent convenient, routinely achievable and recommended time periods for oral rinsing in the clinical setting.23
In light of the findings of this study, the recommended practice
of preprocedural rinsing with hydrogen peroxide in solutions at
concentrations between 1.5% and 3% may not be effective and
therefore the current guidelines from the ADA may need to be
updated. Additional concerns related to local toxicity of hard
and soft tissues from routine use of H2 O2 also requires further
investigation. Furthermore, additional alternatives for patients
unable to use PVP-I oral rinses should be investigated soon.
PVP-I oral rinses at non-toxic dilute concentrations have
been shown to inactivate viruses related to severe acute respiratory syndrome (SARS), middle-east respiratory syndrome
(MERS) and now SARS-CoV-2 as well.7,24,25 Randomized
clinical trials on samples of COVID-19 positive patients comparing dilute PVP-I oral rinses as the standard agent against
other oral rinses is the next important next step in further determination of the ideal pre-procedural rinse strategy for routine dental care. In the interim, dental professionals and patients can benefit from routine preprocedural rinsing with at
least 0.5% PVP-I as it is inexpensive, safe for use in oral cavity up to 2.5%, rarely allergic, easily accessible, and has also
been listed as a broad-spectrum antimicrobial agent for topical uses on the World Health Organization’s List of Essential
Medicines.7,13,26,27 PVP-I at 0.23% concentration is routinely
used in Japan and has also been recommended by the Japanese
Ministry of Health, Labor and Welfare for daily gargling to prevent upper respiratory tract infections.12,24,25 Despite its brown
color PVP-I oral rinse has not been shown to stain teeth or
cause a change in gustatory function.28-30 One clinical trial
showed significantly less staining of PVP-I and higher preference among patients compared to chlorhexidine gluconate.30
The predictable and verifiable in vitro viricidal effect of PVP-I
at very low concentrations and contact times may open up new
possibilities not only in the field of management of viral infectious diseases in medicine, but also in improvement of dental
and medical equipment and related water lines.

Conclusions
SARS-CoV-2 virus was completely inactivated by PVP-I
oral antiseptic rinse in vitro, at all concentrations tested in
as little as 15 seconds. Hydrogen peroxide solutions at the
recommended oral rinse concentrations of 1.5% and 3.0%
showed minimal viricidal effect after contact times as long as
4
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30 seconds. Until further clinical research is available, preprocedural oral rinsing using dilute PVP-I in the range of 0.5%
to 1.5% (for patients and health care providers) should be the
preferred choice over hydrogen peroxide, during the COVID19 pandemic. This additional procedure has the ability to be an
important adjunctive to personal protective equipment, masks
and hand hygiene procedures.
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